Tempe, AZ, December 20, 2017 – SDC, a specialized data services Contract Research Organization (CRO) providing scalable clinical trial solutions via strategic partnerships, congratulates Aerie Pharmaceuticals (Aerie) on their recent announcement that the U.S. Food and Drug Administration (FDA) has approved Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Aerie reports that the FDA approval decision was made two months ahead of the scheduled PDUFA goal date of February 28, 2018.
“It is with great pleasure that we congratulate Aerie Pharmaceuticals on the FDA approval of Rhopressa®,” said Dale W. Usner, Ph.D., President at SDC. “SDC is proud to be a partner on this program, having supported the clinical trials that led to the FDA approval of Rhopressa®. On behalf of all of us at SDC, I extend our sincerest congratulations to the Aerie team on this great accomplishment.”
“We thank SDC for their expertise and support of the Rhopressa® program,” said Tom Mitro, President and COO, Aerie.
For more information, please see the full and original press release dated December 18, 2017: Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa®(netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension.
